Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily
| Autor: | Ernst Schlögl, Peter Valent, Susanne Herndlhofer, Maria-Theresa Krauth, Maria-Theresa Schmook, Gerlinde Mitterbauer-Hohendanner |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Male medicine.medical_specialty Pathology Pleural effusion Dasatinib Antineoplastic Agents Gastroenterology Pericardial effusion Drug Administration Schedule Pericardial Effusion Pleural disease Risk Factors Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine medicine Humans Online Only Articles Aged business.industry Incidence Brief Report Myeloid leukemia Hematology Middle Aged medicine.disease Pleural Effusion Thiazoles Pyrimidines Treatment Outcome Effusion Pleurisy Female business medicine.drug Chronic myelogenous leukemia |
| Zdroj: | Haematologica. 96:163-166 |
| ISSN: | 1592-8721 0390-6078 |
| DOI: | 10.3324/haematol.2010.030494 |
| Popis: | Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily. We examined our chronic myeloid leukemia patients treated with dasatinib at 100 mg or 50 mg daily and identified 4 of 13 patients who developed marked effusion formation. In 2 patients, grade III/IV pleural and/or pericardial effusions were recorded. All 4 patients had received previous anti-leukemia therapy but none had pre-existing cardiac or pulmonary diseases. In 3 patients, dasatinib had to be discontinued despite treatment with diuretics and glucocorticosteroids. In conclusion, dasatinib-treated chronic myeloid leukemia patients are at risk for the development of pleural and pericardial effusions even when the drug is administered at 100 mg or 50 mg daily. Therefore, all patients should be examined for pre-existing comorbidity and risk factors before starting dasatinib and all should have repeated chest X-rays during long-term dasatinib therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|